Tscan Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.53
- Today's High:
- $2.73
- Open Price:
- $2.55
- 52W Low:
- $1.45
- 52W High:
- $5.41
- Prev. Close:
- $2.6
- Volume:
- 60615
Company Statistics
- Market Cap.:
- $117.63 million
- Book Value:
- 3.986
- Revenue TTM:
- $16.41 million
- Operating Margin TTM:
- -503.26%
- Gross Profit TTM:
- $-46284000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.99%
- Return on Equity TTM:
- -50.63%
Company Profile
Tscan Therapeutics Inc had its IPO on 2021-07-16 under the ticker symbol TCRX.
The company operates in the Healthcare sector and Biotechnology industry. Tscan Therapeutics Inc has a staff strength of 135 employees.
Stock update
Shares of Tscan Therapeutics Inc opened at $2.55 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.53 - $2.73, and closed at $2.62.
This is a +0.77% increase from the previous day's closing price.
A total volume of 60,615 shares were traded at the close of the day’s session.
In the last one week, shares of Tscan Therapeutics Inc have increased by +6.5%.
Tscan Therapeutics Inc's Key Ratios
Tscan Therapeutics Inc has a market cap of $117.63 million, indicating a price to book ratio of 0.4211 and a price to sales ratio of 3.4415.
In the last 12-months Tscan Therapeutics Inc’s revenue was $16.41 million with a gross profit of $-46284000 and an EBITDA of $-77050000. The EBITDA ratio measures Tscan Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tscan Therapeutics Inc’s operating margin was -503.26% while its return on assets stood at -21.99% with a return of equity of -50.63%.
In Q2, Tscan Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.4%.
Tscan Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.69 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tscan Therapeutics Inc’s profitability.
Tscan Therapeutics Inc stock is trading at a EV to sales ratio of 1.5271 and a EV to EBITDA ratio of 0.9571. Its price to sales ratio in the trailing 12-months stood at 3.4415.
Tscan Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $316.92 million
- Total Liabilities
- $35.12 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $420000
- Dividend Payout Ratio
- 0%
Tscan Therapeutics Inc ended 2024 with $316.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $316.92 million while shareholder equity stood at $190.61 million.
Tscan Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $35.12 million in other current liabilities, 5000.00 in common stock, $-204987000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $208.84 million and cash and short-term investments were $208.84 million. The company’s total short-term debt was $4,209,000 while long-term debt stood at $29.72 million.
Tscan Therapeutics Inc’s total current assets stands at $208.84 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $31.93 million compared to accounts payable of $3.39 million and inventory worth $-33376000.00.
In 2024, Tscan Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $420000.
Comparatively, Tscan Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.62
- 52-Week High
- $5.41
- 52-Week Low
- $1.45
- Analyst Target Price
- $10.75
Tscan Therapeutics Inc stock is currently trading at $2.62 per share. It touched a 52-week high of $5.41 and a 52-week low of $5.41. Analysts tracking the stock have a 12-month average target price of $10.75.
Its 50-day moving average was $2.24 and 200-day moving average was $2.38 The short ratio stood at 4.87 indicating a short percent outstanding of 0%.
Around 324.1% of the company’s stock are held by insiders while 6967.9% are held by institutions.
Frequently Asked Questions About Tscan Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.